Results for this period
Third quarter1 January 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Sales of Graalpha combination ophthalmic solution were solid in Japan and Asia, but royalties were not included in revenue because the TissueBlue license agreement had expired and the terms of an extension were under discussion. Research and development expenses decreased, mainly reflecting the absence of the U.S. Phase IIb clinical trial for H-1337 conducted in the same period of the previous year.
There is a description of events and other matters relating to the going concern assumption. However, the company recognizes that there is no material uncertainty regarding the going concern assumption, and there are no applicable matters requiring a note on the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | ¥51 million (YoY -82.7%) |
| Operating profit | ¥-483 million |
| Ordinary income | ¥-501 million |
| Profit attributable to owners of the parent | ¥-502 million |
| Net income per share | -¥8.91 |
| Equity ratio | End of the current fiscal period 90.3 / End of previous period 66.1 |
| Total assets | ¥1,372 million |
| Net assets | ¥1,238 million |
| Full-year earnings forecast | Net Sales ¥300 million (YoY -22.6%) / Operating profit ¥-780 million / Ordinary income ¥-800 million / Net income ¥-800 million |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | ¥4,910 thousand |
| Impairment loss | None recorded |
| Breakdown of extraordinary income (loss) | No extraordinary income or extraordinary losses reported |
| Disclosure regarding the going concern assumption | There is a description of events and other matters relating to the going concern assumption. However, the company recognizes that there is no material uncertainty regarding the going concern assumption, and there are no applicable matters requiring a note on the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No additions or removals of consolidated subsidiaries. There were no material changes in the scope of consolidation during the period. |
| Material subsequent events | On 1 October 2026, payment was completed for the total issue price of ¥14,430,000 for the 14th series of stock acquisition rights and for ¥500,000,000 in the 2nd series of unsecured corporate bonds. The proceeds will be used to fund development of H-1337. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (no applicable participants) |
| Issued Shares at Period-End | 57,599,412 |
| Treasury Shares at Period-End | 11,387 |
| Factors Behind Changes in Business Performance | Sales of Graalpha combination ophthalmic solution were solid in Japan and Asia, but royalties were not included in revenue because the TissueBlue license agreement had expired and the terms of an extension were under discussion. Research and development expenses decreased, mainly reflecting the absence of the U.S. Phase IIb clinical trial for H-1337 conducted in the same period of the previous year. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The TissueBlue license agreement expired in December 2025, and royalties from the product were not included in cumulative revenue for the quarter because the terms of an extension are under discussion. Research and development expenses decreased, mainly reflecting the absence of the U.S. Phase IIb clinical trial for H-1337 conducted in the same period of the previous year.